» Articles » PMID: 37368273

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination

Abstract

Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and provide sustained local delivery of immunotherapy. Here, we review the state-of-the-art in this area of research, the challenges and opportunities, with a focus on in situ vaccination to expand the role of radiotherapy in the treatment of both local and metastatic disease. A roadmap for clinical translation is outlined with a focus on specific cancers where such an approach is readily translatable or will have the highest impact. The potential of FLASH radiotherapy to synergize with SRBs is discussed including prospects for using SRBs in place of currently used inert radiotherapy biomaterials such as fiducial markers, or spacers. While the bulk of this review focuses on the last decade, in some cases, relevant foundational work extends as far back as the last two and half decades.

Citing Articles

Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.

Appidi T, China D, Stefan G, Moreau M, Mao S, Velarde E Mol Cancer. 2025; 24(1):68.

PMID: 40050802 PMC: 11883980. DOI: 10.1186/s12943-025-02266-1.


Democratizing FLASH Radiotherapy.

Moreau M, Mao S, Ngwa U, Yasmin-Karim S, China D, Hooshangnejad H Semin Radiat Oncol. 2024; 34(3):344-350.

PMID: 38880543 PMC: 11218907. DOI: 10.1016/j.semradonc.2024.05.001.

References
1.
Hughes J, Parsons J . FLASH Radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy. Int J Mol Sci. 2020; 21(18). PMC: 7556020. DOI: 10.3390/ijms21186492. View

2.
Nguyen L, Ortuno S, Lebrun-Vignes B, Johnson D, Moslehi J, Hertig A . Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Eur J Cancer. 2021; 148:36-47. DOI: 10.1016/j.ejca.2021.01.038. View

3.
Chiang C, Chan S, Lee S, Wong I, Choi H . Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open. 2021; 4(1):e2033761. PMC: 7816108. DOI: 10.1001/jamanetworkopen.2020.33761. View

4.
Sabado R, Balan S, Bhardwaj N . Dendritic cell-based immunotherapy. Cell Res. 2016; 27(1):74-95. PMC: 5223236. DOI: 10.1038/cr.2016.157. View

5.
Noch E, Ramakrishna R, Magge R . Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurg. 2018; 116:505-517. DOI: 10.1016/j.wneu.2018.04.022. View